From: Ceftriaxone-associated pseudolithiasis in hemodialysis patients: a case series study
Pseudolithiasis (n = 10) | No pseudolithiasis (n = 11) | P value | |
---|---|---|---|
Age (years) | 73.9 ± 16.5 | 71.1 ± 18.7 | 0.72 |
Male sex, n (%) | 6 (63.6) | 7 (61.9) | 0.86 |
DM, n (%) | 5 (50.0) | 2 (18.2) | 0.12 |
CVD, n (%) | 5 (50.0) | 4 (36.4) | 0.53 |
Body mass (kg) | 50.1 ± 12.5 | 52.4 ± 9.0 | 0.64 |
Body mass index (kg/m2) | 19.9 ± 4.3 | 20.9 ± 2.8 | 0.53 |
Ca-containing drug, n (%) | 2 (20.0) | 3 (27.3) | 0.70 |
Bed-bound, n (%) | 6 (60.0) | 4 (36.4) | 0.28 |
Fasting, n (%) | 0 (0) | 1 (15.4) | 0.33 |
Laboratory | |||
Albumin (g/dL) | 2.8 ± 0.8 | 3.0 ± 0.6 | 0.35 |
Calcium (mg/dL) | 9.5 ± 0.6 | 9.4 ± 0.6 | 0.75 |
Int-PTH (pg/mL) | 113.0 (81.0–163.0) | 143.0 (94.0–228.0) | 0.61 |
Dose of CTRX (mg/kg/day) | 21.3 (18.1–22.4) | 17.2 (16.1–19.8) | 0.17 |
Duration of CTRX infusion (day) | 12 (8.3–14) | 4 (2–8) | 0.00872* |
Total dose of CTRX (g) | 12.5 (9.3–14) | 4 (2–8) | 0.00476* |